- Previous Close
6,194.05 - Open
6,314.80 - Bid 6,443.15 x --
- Ask 6,454.90 x --
- Day's Range
6,177.20 - 6,462.20 - 52 Week Range
5,850.55 - 10,526.05 - Volume
916 - Avg. Volume
945 - Market Cap (intraday)
147.322B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
27.78 - EPS (TTM)
230.28 - Earnings Date Feb 21, 2025 - Feb 25, 2025
- Forward Dividend & Yield 167.00 (2.61%)
- Ex-Dividend Date May 3, 2024
- 1y Target Est
8,112.75
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
www.sanofiindialtd.com2,174
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SANOFI.BO
View MorePerformance Overview: SANOFI.BO
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SANOFI.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SANOFI.BO
View MoreValuation Measures
Market Cap
147.32B
Enterprise Value
144.91B
Trailing P/E
27.78
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.28
Price/Book (mrq)
21.52
Enterprise Value/Revenue
5.20
Enterprise Value/EBITDA
18.91
Financial Highlights
Profitability and Income Statement
Profit Margin
16.29%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
28.22B
Net Income Avi to Common (ttm)
5.3B
Diluted EPS (ttm)
230.28
Balance Sheet and Cash Flow
Total Cash (mrq)
2.48B
Total Debt/Equity (mrq)
3.23%
Levered Free Cash Flow (ttm)
--